Ung Quoted in Bloomberg Law About Process for Health Care Providers to Receive Relief Aid
11 June 2020
Partner Diane Ung was quoted in the Bloomberg Law article, “Medicaid Providers Fear Delay in Getting Promised Relief Aid,” about the process non-hospital providers eligible for relief aid from the Department of Health and Human Services will have to navigate in order to apply for the aid.
Those providers eligible for the funding will be required to submit revenue information through a new online provider portal and await validation of their claims before seeing any money. The process may include some back and forth between HHS and providers, some of whom may be asked to provide additional information.
Information that the providers must submit include federal tax returns for 2017-2019, the first quarter federal tax return for 2020, a federal unemployment tax return, a worksheet for calculating the provider’s number of full-time employees, and a worksheet for calculating gross revenue.
Interacting with the portal could be daunting for some smaller providers, Ung said. “Many smaller providers have less experience with reporting this kind of data,” she said. “We’re talking about pediatricians and dentists here, they haven’t been required to do much of this, and they could find it intimidating.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”